



Author index

Volume 127 (1996)

A. Ades, P., see Fonong, T. 127, 177
Abbot, S.E., see Thorne, S.A. 127, 167
Ahmadi, R., see Maca, T. 127, 27
Alain Simon, see Linhart, A. 127, 103
Aro, A., see Öhrvall, M. 127, 65
Aston, C.E., see Kamboh, M.I. 127, 255
Auerbach, B.J., see Krause, B.R. 127, 91

Balagtas, C.C., see Schaefer, E.J. 127, 113
Barnett, B.C., see Krause, B.R. 127, 91
Berenson, G.S., see Srinivasan, S.R. 127, 73
Berglund, L., see Öhrvall, M. 127, 65
Bisgaier, C.L., see Krause, B.R. 127, 91
Black, D.M., see Schaefer, E.J. 127, 113
Blake, D.R., see Thorne, S.A. 127, 167
Bobryshev, Y.V., J.A. Crozier, R.S.A. Lord, D. Tran, O.S. Jamal, H.N. Pärsson, K.F. Scott, Expression of secretory group II phospholipase A2 by CD1a positive cells in human atherosclerotic plaques 127, 283
Bode-Böger, S.M., see Böger, R.H. 127, 1
Böger, R.H., S.M. Bode-Böger, J.C. Frölich, The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications 127, 1
Bousley, R., see Krause, B.R. 127, 91
Brüel, A., H. Oxlund, Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age 127, 155
Byrne, C.D., N.J. Wareham, P.K. Mistry, D.I.W. Phillips, N.D. Martensz, D. Halsall, P.J. Talmud, S.E. Humphries, C.N. Hales, The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide 127, 35

Calles-Escandon, J., see Fonong, T. 127, 177
Casao, E., see Civeira, F. 127, 273
Castro, G., see Syvänenne, M. 127, 245
Catapano, A.L., see Lambert, D.A. 127, 205

Catapano, A.L., see Roma, P. 127, 147
Cenarro, A., see Civeira, F. 127, 273
Chen, W.-J., S.-Y. Lin-Shiau, H.-C. Huang, Y.-T. Lee, Ischemia-induced alteration of myocardial Na⁺-K⁺-ATPase activity and ouabain binding sites in hypercholesterolemic rabbits 127, 59
Chen, Y.-L., see Liu, M.W. 127, 221
Cilla Jr, D.D., see Schaefer, E.J. 127, 113
Civeira, F., M. Pocoví, A. Cenarro, E. Casao, E. Vilella, J. Joven, J. González, A.L. García-Otín, J.M. Ordovás, Apo E variants in patients with type III hyperlipoproteinemia 127, 273
Cole, T., see Schaefer, E.J. 127, 113
Crozier, J.A., see Bobryshev, Y.V. 127, 283

De Geitere, C., see Syvänenne, M. 127, 245
Dengremont, C., see Syvänenne, M. 127, 245
Derfler, K., see Maca, T. 127, 27
Du, R.Y., see He, Y. 127, 229

Ehnholm, C., see Srinivasan, S.R. 127, 73
Ehnholm, C., see Syvänenne, M. 127, 245
Ehringer, H., see Maca, T. 127, 27
Elkhalil, L., see Luc, G. 127, 131
Essenburg, A.D., see Krause, B.R. 127, 91

Figueroa, J.E., see Vijayagopal, P. 127, 195
Fonong, T., M.J. Toth, P. A. Ades, L.I. Katzel, J. Calles-Escandon, E.T. Poehlman, Relationship between physical activity and HDL-cholesterol in healthy older men and women: a cross-sectional and exercise intervention study 127, 177
Fontenot, J.D., see Vijayagopal, P. 127, 195
Franceschini, G., see Syvänenne, M. 127, 245
Frölich, J.C., see Böger, R.H. 127, 1
Fujiwara, R., T. Nakai, Effects of glucose, insulin, and insulin-like growth factor-I on glucose transport activity in cultured rat vascular smooth muscle cells 127, 49

Ganotakis, E.S., see Mikhailidis, D.P. 127, 287
 Garcia-Otin, A.L., see Civeira, F. 127, 273
 Gariepy, J., see Linhart, A. 127, 103
 Giral, P., see Linhart, A. 127, 103
 Glancy, D.L., see Vijayagopal, P. 127, 195
 González, J., see Civeira, F. 127, 273
 Gotto Jr., A.M., see Lambert, D.A. 127, 205
 Groszek, L., see Lin, J.H.-C. 127, 185
 Gylling, H., H. Relas, H.E. Miettinen, R. Radhakrishnan, T.A. Miettinen, Delayed postprandial retinyl palmitate and squalene removal in a patient heterozygous for apolipoprotein A-I_{FIN} mutation (Leu 159→Arg) and low HDL cholesterol level without coronary artery disease 127, 239

Hales, C.N., see Byrne, C.D. 127, 35
 Halsall, D., see Byrne, C.D. 127, 35
 Hamman, R.F., see Kamboh, M.I. 127, 255
 He, Y., T.H. Lam, L.S. Li, L.S. Li, R.Y. Du, G.L. Jia, J.Y. Huang, J.S. Zheng, The number of stenotic coronary arteries and passive smoking exposure from husband in lifelong non-smoking women in Xi'an, China 127, 229
 Hörl, W.-H., see Maca, T. 127, 27
 Huang, H.-C., see Chen, W.-J. 127, 59
 Huang, J.Y., see He, Y. 127, 229
 Humphries, S.E., see Byrne, C.D. 127, 35

Ikäheimo, M., see Korhonen, T. 127, 213

Jamal, O.S., see Bobryshev, Y.V. 127, 283
 Jauhainen, M., see Syvänen, M. 127, 245
 Jean-Charles Fruchart, see Luc, G. 127, 131
 Jia, G.L., see He, Y. 127, 229
 Joven, J., see Civeira, F. 127, 273

Kahri, J., see Syvänen, M. 127, 245
 Kamboh, M.I., C.E. Aston, C.M. Nestlerode, A.E. McAllister, R.F. Hamman, Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of Apo A-I and HDL-cholesterol 127, 255
 Katzel, L.I., see Fonong, T. 127, 177
 Kervinen, K., see Korhonen, T. 127, 213
 Kesäniemi, Y.A., see Korhonen, T. 127, 213
 Khachadurian, A.K., see Rifici, V.A. 127, 19
 Kieft, K.A., see Krause, B.R. 127, 91
 Kobari, Y., see Lin, J.H.-C. 127, 185
 Koistinen, M.J., see Korhonen, T. 127, 213
 Koppensteiner, R., see Maca, T. 127, 27
 Korhonen, T., M.J. Savolainen, M.J. Koistinen, M. Ikäheimo, M.K. Linnaluoto, K. Kervinen, Y.A. Kesäniemi, Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women 127, 213
 Krause, B.R., B.C. Barnett, A.D. Essenburg, K.A. Kieft, B.J. Auerbach, R. Bousley, R. Stanfield, R.S. Newton, C.L. Bisgaier, Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats 127, 91
 Kuroiwa, A., see Nakashima, Y. 127, 43

Lambert, D.A., A.L. Catapano, L.C. Smith, J.T. Sparrow, A.M. Gotto Jr., Effect of the apolipoprotein C-II/C-III ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles 127, 205
 Lamson-Fava, S., see Schaefer, E.J. 127, 113
 Lam, T.H., see He, Y. 127, 229
 Lee, Y.-T., see Chen, W.-J. 127, 59
 Lehmann, E.D., Functional abnormalities of the aorta 127, 139
 Levenson, J., see Linhart, A. 127, 103
 Liao, H.L., see Lin, J.H.-C. 127, 185
 Li, L.S., see He, Y. 127, 229
 Li, L.S., see He, Y. 127, 229
 Linhart, A., J. Gariepy, P. Giral, J. Levenson, Alain Simon, Carotid artery and left ventricular structural relationship in asymptomatic men at risk for cardiovascular disease 127, 103
 Lin, J.H.-C., Y. Zhu, H.L. Liao, Y. Kobari, L. Groszek, M.B. Stemerman, Induction of vascular cell adhesion molecule-1 by low-density lipoprotein 127, 185
 Linnaluoto, M.K., see Korhonen, T. 127, 213
 Lin-Shiau, S.-Y., see Chen, W.-J. 127, 59
 Lin, S.-J., see Liu, M.W. 127, 221
 Lithell, H., see Öhrvall, M. 127, 65
 Liu, M.W., S.-J. Lin, Y.-L. Chen, Local alcohol delivery may reduce phenotype conversion of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury 127, 221
 Lord, R.S.A., see Bobryshev, Y.V. 127, 283
 Lottenberg, A.M.P., see Lottenberg, S.A. 127, 81
 Lottenberg, S.A., A.M.P. Lottenberg, V.S. Nunes, R. McPherson, E.C.R. Quintão, Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in Type II diabetics and normal controls 127, 81
 Luc, G., Z. Majd, P. Poulain, L. El Khalil, Jean-Charles Fruchart, Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction 127, 131

Maca, T., R. Ahmadi, K. Derfler, W.-H. Hörl, R. Koppensteiner, E. Minar, B. Schneider, A. Stümpflen, H. Ehringer, Elevated Lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? 127, 27
 Majd, Z., see Luc, G. 127, 131
 Makino, N., see Sugano, M. 127, 123
 Martensz, N.D., see Byrne, C.D. 127, 35
 McAllister, A.E., see Kamboh, M.I. 127, 255
 McPherson, R., see Lottenberg, S.A. 127, 81
 Michelagnoli, S., see Syvänen, M. 127, 245
 Miettinen, H.E., see Gylling, H. 127, 239
 Miettinen, T.A., see Gylling, H. 127, 239
 Mikhailidis, D.P., E.S. Ganotakis, A.F. Winder, Comment on: Effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia 127, 287

Mills, P.G., see Thorne, S.A. **127**, 167
 Minar, E., see Maca, T. **127**, 27
 Mistry, P.K., see Byrne, C.D. **127**, 35

Nakai, T., see Fujiwara, R. **127**, 49
 Nakashima, Y., T. Toyokawa, S. Tanaka, K. Yamashita, A. Yashiro, H. Tasaki, A. Kuroiwa, Simvastatin increases plasma NO₂⁻ and NO₃⁻ levels in patients with hypercholesterolemia **127**, 43
 Nestlerode, C.M., see Kamboh, M.I. **127**, 255
 Newton, R.S., see Krause, B.R. **127**, 91
 Niculescu, F., see Rus, H.G. **127**, 263
 Nunes, V.S., see Lottenberg, S.A. **127**, 81

Öhrvall, M., L. Berglund, I. Salminen, H. Lithell, A. Aro, B. Vessby, The serum cholesterol ester fatty acid composition but not the serum concentration of alpha tocopherol predicts the development of myocardial infarction in 50-year-old men: 19 years follow-up **127**, 65
 Ordovás, J.M., see Civeira, F. **127**, 273
 Oxlund, H., see Brüel, A. **127**, 155

Pärsson, H.N., see Bobryshev, Y.V. **127**, 283
 Phillips, D.I.W., see Byrne, C.D. **127**, 35
 Pocoví, M., see Civeira, F. **127**, 273
 Poehlman, E.T., see Fonong, T. **127**, 177
 Poulaïn, P., see Luc, G. **127**, 131

Quintão, E.C.R., see Lottenberg, S.A. **127**, 81

Radhakrishnan, R., see Gylling, H. **127**, 239
 Rainwater, D.L., Lp(a) concentrations are related to plasma lipid concentrations **127**, 13
 Relas, H., see Gylling, H. **127**, 239
 Rifici, V.A., A.K. Khachadurian, Effects of dietary vitamin C and E supplementation on the copper mediated oxidation of HDL and on HDL mediated cholesterol efflux **127**, 19
 Roma, P., A.L. Catapano, Stress proteins and atherosclerosis **127**, 147
 Rowan, J.P., see Schaefer, E.J. **127**, 113
 Rus, H.G., R. Vlaicu, F. Niculescu, Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall **127**, 263

Salminen, I., see Öhrvall, M. **127**, 65
 Savolainen, M.J., see Korhonen, T. **127**, 213
 Schaefer, E.J., S. Lamont-Fava, T. Cole, D.L. Sprecher, D.D. Cilla Jr, C.C. Balagtas, J.P. Rowan, D.M. Black, Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels **127**, 113
 Schneider, B., see Maca, T. **127**, 27
 Scott, K.F., see Bobryshev, Y.V. **127**, 283
 Smith, L.C., see Lambert, D.A. **127**, 205
 Sparrow, J.T., see Lambert, D.A. **127**, 205

Sprecher, D.L., see Schaefer, E.J. **127**, 113
 Srinivasan, S.R., C. Ehnholm, W.A. Wattigney, G.S. Berenson, Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6-year period. The Bogalusa Heart Study **127**, 73
 Stanfield, R., see Krause, B.R. **127**, 91
 Stemerman, M.B., see Lin, J.H.-C. **127**, 185
 Stevens, C.R., see Thorne, S.A. **127**, 167
 Stümpflen, A., see Maca, T. **127**, 27
 Sugano, M., N. Makino, T. Yanaga, The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits **127**, 123
 Syvänen, M., G. Castro, C. Dengremont, C. De Geitere, M. Jauhainen, C. Ehnholm, S. Michelagnoli, G. Franceschini, J. Kahri, M.-R. Taskinen, Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein **127**, 245

Talmud, P.J., see Byrne, C.D. **127**, 35
 Tanaka, S., see Nakashima, Y. **127**, 43
 Tasaki, H., see Nakashima, Y. **127**, 43
 Taskinen, M.-R., see Syvänen, M. **127**, 245
 Thorne, S.A., S.E. Abbot, C.R. Stevens, P.G. Winyard, P.G. Mills, D.R. Blake, Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells **127**, 167
 Toth, M.J., see Fonong, T. **127**, 177
 Toyokawa, T., see Nakashima, Y. **127**, 43
 Tran, D., see Bobryshev, Y.V. **127**, 283
 Tsuda, Y., Response to Mikhailidis et al. **127**, 289

Vessby, B., see Öhrvall, M. **127**, 65
 Vijayagopal, P., J.E. Figueroa, J.D. Fontenot, D.L. Glancy, Isolation and characterization of a proteoglycan variant from human aorta exhibiting a marked affinity for low density lipoprotein and demonstration of its enhanced expression in atherosclerotic plaques **127**, 195
 Vilella, E., see Civeira, F. **127**, 273
 Vlaicu, R., see Rus, H.G. **127**, 263

Wareham, N.J., see Byrne, C.D. **127**, 35
 Wattigney, W.A., see Srinivasan, S.R. **127**, 73
 Winder, A.F., see Mikhailidis, D.P. **127**, 287
 Winyard, P.G., see Thorne, S.A. **127**, 167

Yamashita, K., see Nakashima, Y. **127**, 43
 Yanaga, T., see Sugano, M. **127**, 123
 Yashiro, A., see Nakashima, Y. **127**, 43

Zheng, J.S., see He, Y. **127**, 229
 Zhu, Y., see Lin, J.H.-C. **127**, 185





Subject index

Volume 127 (1996)

Adiposity 127, 177
Ageing 127, 155
Alcohol 127, 221
Angiography 127, 229
Angiotensin-converting enzyme inhibitor 127, 123
Angiotensin II receptor antagonist 127, 123
Antioxidant vitamins 127, 19
Aorta 127, 139, 155
AP-1 127, 185
Apo B lipoproteins 127, 81
Apo E_{Christchurch} 127, 273
Apo E genotyping 127, 273
Apo E polymorphism 127, 73
Apo E polymorphisms 127, 273
Apolipoprotein(a) 127, 13
Apolipoprotein(a) genotypes 127, 13
Apolipoprotein A-I 127, 255
Apolipoprotein A-I mutation 127, 239
Apolipoprotein B 127, 35
Apolipoprotein B-48 127, 239
Apolipoprotein E 127, 213, 273
Apolipoproteins 127, 91, 131, 205
Apolipoprotein-specific particles 127, 245
Arteriosclerosis 127, 229
Atherogenesis 127, 195, 263
Atherosclerosis 127, 1, 123, 147, 283

Balloon injury 127, 221
Biomechanics 127, 155
– 75 bp 127, 255
+ 83 bp 127, 255

Calcification 127, 283
Cardiovascular risk factors 127, 103
Carotid artery 127, 103
C5b-9 127, 263
CD1a 127, 283
Childhood risk factors 127, 73
Cholesterol 127, 13, 91, 113
Cholesterol efflux 127, 19

Cholesterol-lowering agent 127, 43
Cholesteryl ester transfer protein 127, 81
Collagen 127, 155
Complement activation 127, 263
Compliance 127, 139
Coronary 127, 229
Coronary artery disease 127, 239
Coronary smooth muscle cells 127, 167
Coronary stenosis 127, 213
Cytotoxic stimuli 127, 147

Distensibility 127, 139
Dysbetalipoproteinemia 127, 273

E-4177 127, 123
Echocardiography 127, 103
Elastin 127, 155
Elderly 127, 177
Enalapril 127, 123
Endothelial cells 127, 185
Environmental tobacco smoke 127, 229
Epidemiologic methods 127, 229
Extent of coronary disease 127, 229

Fatty acid composition 127, 65
Female 127, 213
Fibrates 127, 91
Foam cell formation 127, 195
Free fatty acid 127, 35

GATA 127, 185
Gemfibrozil 127, 113
Genotype 127, 35
Glucose transport activity 127, 49
Glycation 127, 155

Haplotypes 127, 255
HDL-C 127, 177
HDL cholesterol 127, 239
High density lipoprotein 127, 113

High-density lipoprotein 127, 81
 High density lipoprotein 127, 19
 High density lipoproteins 127, 245
 Human 127, 13
 Hypercholesterolemia 127, 43, 59, 185
 hypercholesterolemic 127, 289

IL-8 127, 263
 IL-6 127, 263
 Inflammation 127, 283
 Insulin 127, 49
 Insulin-like growth factor-I 127, 49
 Insulin resistance 127, 49
 Interstitial fluid 127, 131
 Intimal hyperplasia 127, 221
 Intima-media thickness 127, 103
 In vitro cholesterol efflux 127, 245
 Ischemia 127, 59

L-Arginine 127, 1
 LDL-binding 127, 195
 LDL/HDL ratio 127, 65
 Lecithin cholesterol acyltransferase 127, 81
 Lecithin:cholesteryl acyltransferase 127, 245
 Left ventricular mass 127, 103
 Linkage disequilibrium 127, 255
 Lipid transfer proteins 127, 245
 Lipoprotein(a) 127, 13, 27
 Lipoprotein lipase 127, 205
 Lipoproteins 127, 73, 91, 131
 Low density lipoprotein 127, 113, 167

Male 127, 213
 Monocyte adhesion 127, 167
 Myocardial infarction 127, 65, 131

Na⁺-K⁺-ATPase 127, 59
 Nitric oxide 127, 1
 Non-insulin dependent diabetes mellitus 127, 81
 Non-smokers 127, 255

Ouabain receptor 127, 59
 Oxidation 127, 19

Percutaneous transluminal angioplasty 127, 27
 Peripheral arterial occlusive disease 127, 27
 Phosphatidylinositol 3-kinase 127, 49
 Phospholipase A2 127, 283
 Physical activity 127, 177
 Plasma fibrinogen 127, 287, 289
 Plasma lipids 127, 213
 Plasma nitrite and nitrate 127, 43
 Postprandial lipoproteins 127, 239
 Pravastatin 127, 287
 Pravastatin sodium 127, 289
 Promoter activation 127, 185
 Protein cofactors 127, 205
 Proteoglycans 127, 195
 Pulse wave velocity 127, 139

Restenosis 127, 27
 Retinyl palmitate 127, 239
 Reverse cholesterol transport 127, 245

Simvastatin 127, 287, 289
 Smooth muscle cells 127, 221
 Squalene 127, 239
 Stiffness 127, 139
 Stress proteins 127, 147
 Systolic blood pressure 127, 65

Therapeutic implications 127, 1
 Tocopherol 127, 65
 Tracking 127, 73
 Triacylglycerides 127, 13
 Triglyceride 127, 35, 91
 Triglyceride-rich lipoprotein 127, 35
 Triglycerides 127, 113
 Type II hyperlipoproteinemia 127, 287
 Type III hyperlipoproteinemia 127, 273

US Whites 127, 255

Vascular adhesion molecule 127, 185
 Vascular dendritic cells 127, 283
 Vascular smooth muscle cells 127, 49